A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTC21C in Subjects With Plasma Cell-driven Autoimmune Diseases
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs SCTC 21 (Primary)
- Indications IgA nephropathy
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sinocelltech
- 21 Jan 2025 New trial record